Posttransplant lymphoproliferative disorder after living donor liver transplant: are we improving incidence and outcome?

摘要

Posttransplant lymphoproliferative disorders (PTLDs), a group of B-cell (and less frequently, T-cell) lymphomas, develop as a complication of immunosuppression in patients undergoing organ transplant [1]. The first report of PTLD was in 1969 [2] by Penn and colleagues, but since then, it has been reported after different kinds of organ transplant and has become an entity of interest and research worldwide. Since the initial description, PTLD has been shown to have a wide variation in clinical presentation, time of appearance, etiology, histopathology, and therapy. However, overall it represents a potentially life-threatening complication of transplant.